RxDoctor Payments Data

Jose Labault-Santiago, MD

Neurology · Atlantis, FLNPI 1932358009

Payments from drug & device makers

$12,466in general payments, 2019–2025

Across 605 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • UCB, Inc.$2K
  • Pfizer$1K
  • Biohaven Pharmaceuticals, Inc.$796
  • MDD US Operations, LLC$761
  • Eisai Inc.$617
  • plus $5K from 39 others

What the payments were for

  • Speaking & faculty fees$1101%
  • Food & beverage$12,34299%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,466 in reported general payments places this provider in the 65th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$212,331
Medicare patients
515
Services billed
14,005

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyvgartEfgartigimod Alfa-Fcab28$1,818,459
GammakedImmune Globul G/Gly/Iga Avg 4636$1,113,075
PanzygaImmun Glob G(Igg)-Ifas/Glycine52$945,406
OctagamImmun Globg(Igg)/Malt/Iga Ov5038$821,918
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5031$593,824
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5039$520,735
Gamunex-CImmune Globul G/Gly/Iga Avg 4634$451,015
BotoxOnabotulinumtoxina125$142,200
Aimovig AutoinjectorErenumab-Aooe22$21,231
UbrelvyUbrogepant16$17,547
Pyridostigmine Bromide140$11,300
Gabapentin666$9,281
Epinephrine14$3,892
Pregabalin218$3,366
Dimethyl Fumarate13$2,320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Argenx US, Inc.Vyvgart$212$1,818,45928 claims
PfizerPanzyga, Octagam$1,052$1,767,32490 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$444$593,82431 claims
AbbVieBotox, Ubrelvy$2,656$159,748141 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$14$13,609185 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,434 neurology providers in Florida.

Other neurology in Atlantis

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →